NervGen Pharma released expanded CONNECT SCI data showing durable and broad functional improvements in people with chronic spinal cord injury treated with NVG‑291. The company presented week‑16 follow‑up and blinded exit interviews up to 364 days, reporting gains in motor function, bladder control and reduced spasticity versus placebo. NervGen also said the FDA confirmed multiple regulatory pathways could support approval for NVG‑291. The data combine clinical outcomes with neurophysiologic biomarkers—reduced hyperactive reticulospinal signaling and increased corticospinal signaling—to suggest a biological basis for repair. NervGen will pursue regulator meetings and further development; investors and SCI clinicians will scrutinize randomized effect sizes, durability, and safety to assess whether NVG‑291 could become the first pharmacologic therapy to restore function after chronic SCI.